Clinical Scorecard: Complement Inhibition for Geographic Atrophy
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) |
| Key Mechanisms | Dysregulation of the complement system contributes to GA pathogenesis; complement inhibition slows GA progression. |
| Target Population | Patients aged ≥60 years with baseline best-corrected visual acuity of at least 24 ETDRS letters and GA areas ranging from 2.5 mm² to 17.5 mm². |
| Care Setting | Ophthalmology clinics and specialized treatment centers. |
Key Highlights
- FDA approved pegcetacoplan and avacincaptad pegol for GA treatment in 2023.
- Pegcetacoplan slows GA growth by 19% to 22% with monthly therapy.
- Risk of developing neovascular AMD (nAMD) is dose-dependent with pegcetacoplan; higher doses may increase risk.
- Chronic low-grade inflammation is a key driver of AMD progression.
- Complement factor H mutations correlate with higher risk of AMD.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and GA area using standardized measures.
Management
- Consider intravitreal complement inhibitors for slowing GA progression.
Monitoring & Follow-up
- Regularly evaluate for progression to nAMD and visual function; recommend evaluations every 3-6 months.
Risks
- Monitor for dose-dependent risk of nAMD and retinal vasculitis.
Patient & Prescribing Data
Patients with AMD-associated GA, particularly those with risk factors for nAMD.
Pegcetacoplan shows potential to limit GA growth but does not significantly improve secondary visual function endpoints; implications for patient quality of life should be discussed.
Clinical Best Practices
- Educate patients on the risks of nAMD associated with pegcetacoplan.
- Implement regular follow-ups to monitor visual acuity and signs of nAMD.
- Consider genetic testing for complement factor H mutations in high-risk patients; educate patients on its importance.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
